Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report

Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report

Weiwei Kong,1,2 Jia Wei,1 Juan Liu,1 Yudong Qiu,3 Jiong Shi,4 Jian He,5 Mu Su,6 Mingzhe Xiao,7 Baorui Liu11The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, People&rsquo...

Full description

Bibliographic Details
Main Authors:	Kong W, Wei J, Liu J, Qiu Y, Shi J, He J, Su M, Xiao M, Liu B
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-07-01
Series:	OncoTargets and Therapy
Subjects:	Immunotherapy radiotherapy PD-L1 biomarker GBC
Online Access:	https://www.dovepress.com/significant-benefit-of-nivolumab-combining-radiotherapy-in-metastatic--peer-reviewed-article-OTT

Similar Items

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
by: Chen, C., et al.
Published: (2022)

Preoperative fasting hyperglycemia is an independent prognostic factor for postoperative survival after gallbladder carcinoma radical surgery
by: Zheng P, et al.
Published: (2019-02-01)

Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma
by: Jeong Il Yu, et al.
Published: (2019-11-01)

First-line treatment of metastatic melanoma: role of nivolumab
by: Force J, et al.
Published: (2017-02-01)

Long Non-Coding RNA Myosin Light Chain Kinase Antisense 1 Plays an Oncogenic Role in Gallbladder Carcinoma by Promoting Chemoresistance and Proliferation
by: Li Y, et al.
Published: (2021-08-01)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
by: Yuehong Kong, et al.
Published: (2021-03-01)

Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report
by: Lazzari G, et al.
Published: (2018-08-01)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020-02-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review
by: Xiangrong Zhao, et al.
Published: (2020-09-01)

The Diagnostic Accuracy of CT Scan in Evaluation of Gallbladder Carcinoma
by: Nasreen Naz, et al.
Published: (2016-04-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
by: Su X, et al.
Published: (2020-04-01)

Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient
by: Clara Milhem, et al.
Published: (2020-09-01)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021-06-01)

Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
by: Rodolfo Chicas-Sett, et al.
Published: (2019-05-01)

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review
by: Yan Z, et al.
Published: (2020-07-01)

Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis
by: Shuang Wu, et al.
Published: (2021-03-01)

Integration between GBC Historic Building® and BIM: the methodological innovation for conservation project workflow
by: Federico Ferrari, et al.
Published: (2016-06-01)

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
by: Maike Trommer, et al.
Published: (2019-05-01)

MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
by: Zhen Tao, et al.
Published: (2018-07-01)

Corrigendum: Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
by: Maike Trommer, et al.
Published: (2020-01-01)

Integrated Proteomic and Phosphoproteomics Analysis of DKK3 Signaling Reveals Activated Kinase in the Most Aggressive Gallbladder Cancer
by: Kirti Gondkar, et al.
Published: (2021-02-01)

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
by: Brooke C. Bloom, et al.
Published: (2019-04-01)

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report
by: Lyu M, et al.
Published: (2020-05-01)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
by: Ou Yamaguchi, et al.
Published: (2019-04-01)

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
by: Farastuk Bozorgmehr, et al.
Published: (2019-11-01)

Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma
by: Lea Bottlaender, et al.
Published: (2017-07-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

The Effect and Mechanism of Vascular Endothelial Growth Factor (VEGF) on Tumor Angiogenesis in Gallbladder Carcinoma
by: Dongqing XU, et al.
Published: (2019-04-01)

Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma
by: Kirtesh R. Patel, et al.
Published: (2018-07-01)

FOCUS ON NIVOLUMAB IN NSCLC
by: Diego Luigi Cortinovis, et al.
Published: (2016-12-01)

Insights From the Analysis of Clinicopathological and Prognostic Factors in Patients With Gallbladder Cancer
by: An, Y., et al.
Published: (2022)

Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
by: Chuling Li, et al.
Published: (2019-10-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
by: David J. Pinato, et al.
Published: (2021-03-01)

PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer
by: Savić Ivana, et al.
Published: (2018-01-01)

Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
by: D. E. Meyers, et al.
Published: (2018-03-01)